Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Abroad (travel likely)Recruiting

Conditions

Choroidal Melanoma · Indeterminate Lesions · Uveal Melanoma · Ocular Melanoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Eye Research Australia, East Melbourne, Victoria, Australia

Study leads

Study Director
Aura Biosciences

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Choroidal Melanoma · Indeterminate Lesions · Uveal Melanoma

IsraelRecruitingPHASE3

Birmingham, United States · La Jolla, United States

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma · Uveal Melanoma, Metastatic · Uveal Melanoma, Recurrent

Abroad (travel likely)RecruitingPHASE1, PHASE2

Scottsdale, United States · Denver, United States

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Uveal Melanoma

IsraelRecruitingPHASE3

Scottsdale, United States · La Jolla, United States